Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Novo Nordisk's Obesity Care Sales Drive 1Q Results | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Novo Nordisk’s Obesity Care Sales Drive 1Q Results

Obesity care sales grew by 131% to DKK 7.8 billion mainly driven by the uptake of Wegovy in the U.S.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Novo Nordisk
1Q Revenues: 53.4 DKK billion (+27%). $7.8 billion
1Q Earnings: 19.8 DKK billion (+39%) $2.9 billion
Comments: Sales within Diabetes and Obesity care increased by 33% to DKK 48.8 billion, mainly driven by GLP-1 diabetes sales growth of 54%. Rare disease sales decreased 15% reflecting a temporary reduction in manufacturing output. Obesity care sales grew by 131% to DKK 7.8 billion mainly driven by the uptake of Wegovy in the U.S. A second contract manufacturer for Wegovy initiated production in April 2023. Novo Nordisk successfully completed the PIONEER PLUS phase 3 trial with oral semaglutide 25 mg and 50 mg demonstrating superior reductions in HbA1c and body weight versus 14 mg in people with type 2 diabetes.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters